Navigation Links
YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
Date:1/20/2011

MISSISSAUGA, ON, Jan. 20 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, today announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea.

"The overall findings of the study are positive, and support the promise of nimotuzumab in this important global cancer market. Although not powered for statistical significance, in subgroup analyses these data demonstrated that EGFR-positive patients treated with nimotuzumab showed a potential improvement of Progression Free Survival and Overall Survival in gastric cancer. This is consistent with evidence that nimotuzumab selectively targets tissues over-expressing EGFR," said Dr. Nick Glover, President and CEO of YM BioSciences. "The authors of the study conclude that the selection of gastric cancer patients by EGFR status might be effective for future studies of nimotuzumab, and indicate that a Phase III clinical trial should be performed to examine these findings."

The results were reported in a poster being presented on January 20, 2011 at the ASCO Gastrointestinal Cancers Symposium in San Francisco, entitled: "Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results".

Trial Design and Results:

The study is a Phase II multi-center, randomized, open-label trial evaluating nimotuzumab ("N") (400 mg, IV weekly) plus irinotecan ("I") (150 mg/m2 IV every two weeks) compared to irinotecan alone in patients with advanced or recurrent gastric cancer who are refractory to a 5-fluorouracil-based regimen. The efficacy analysis was condu
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DIEGO , Aug. 3, 2015  Halozyme Therapeutics, ... Update Conference Call for the second quarter 2015 on ... PT. Dr. Helen Torley , president and chief ... date post-market, Halozyme will release financial results for the ... webcast live through the "Investors" section of Halozyme,s corporate ...
(Date:8/3/2015)... 3, 2015  Merck KGaA, Darmstadt, Germany ... high-tech products in the healthcare, life science and performance ... Nano-C, their development and launch of promising new fullerene ... Merck KGaA, Darmstadt, Germany , is ... sector. Novel derivatives: highly stable, easy to ...
(Date:8/3/2015)... NEW YORK , August 3, 2015 ... "Global Market Study on 3D Cell Culture: ... published by Persistence Market Research, the global 3D cell culture ... is expected to expand at a CAGR of 29.1% ... View Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp ...
(Date:7/31/2015)... China Cord Blood Corporation (NYSE: CO) ("CCBC" ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has filed its Annual Report on ... The filed Form 20-F includes audited financial statements for ... 20-F can be accessed by visiting the U.S. Securities ...
Breaking Biology Technology:Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... Prevalence and Roles of miRNAs , ... cloned , and sequenced from human ... apparently regulates multiple genes, and miRNAs are thought to , ... predict mRNA target sites for miRNAs [2,3]. A handful of these , ...
... Construction Kit , Prepare your probe in ... Ideal for siRNA/miRNA studies , ... high specific , activity RNA probes for RPA, Northern, Southern, ... No cloning required , ...
... , with a fluorometer capable of ... ultra-sensitive assay for determining RNase A specific activity. The , ... including RNase A, T1, RNase I, micrococcal ... nuclease, and Benzonase. In addition to detecting , ...
Cached Biology Technology:Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 2Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 3Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 4Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 5Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 6Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 7Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 8Reagents for Up and Down-Regulation of miRNA Activity in Mammalian Cells 9Prepare siRNA and miRNA Probes in Just 1 Hour 2Prepare siRNA and miRNA Probes in Just 1 Hour 3Measuring RNase Activity A Real-time Kinetic Analysis 2Measuring RNase Activity A Real-time Kinetic Analysis 3Measuring RNase Activity A Real-time Kinetic Analysis 4Measuring RNase Activity A Real-time Kinetic Analysis 5
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
(Date:7/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), a leading developer ... report financial results for the fourth quarter and fiscal ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-455-2260 (conference ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... period of torpor to conserve energy when resources are scarce. ... champion by far among vertebrates is the burrowing frog ( ... in the mud in the absence of any food or ... scientists at the University of Queensland have discovered that the ...
... new arsenal for meningitis treatment and the war on ... developed by scientists at the Institute of Bioengineering and ... Nanotechnology . The stable bioengineered nanoparticles devised at ... cells that could cause fatal infections and are highly ...
... new song from a member of its own species, the experience ... The sequential switching on and off of thousands of genes after ... memory in the songbird brain. The finding, detailed this month ... was a surprise, said principal investigator David Clayton, a professor of ...
Cached Biology News:Super-sleepers could help super-sizers! 2Singapore nanotechnology combats fatal brain infections 2Researchers see evidence of memory in the songbird brain 2
... combines 2 products into 1:, , A ... isolation kit , ,The FastPrep System ... Qbiogene/BIO101 System Matrix and Isolation Kits. Samples ... tubes eliminating the use of metal probes ...
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
Sterile, individually wrapped, 4mm Cuvettes...
... III RNase H- Reverse ... improved version of SuperScript™ ... Like SuperScript™ II it ... strand from single-stranded RNA ...
Biology Products: